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air lift = 1 vvm
Tgrowth = 37°C, 
time growth = 2 h
Texpression= 25 °C 
time expression = 6, 10 and 16h 
Expression: 
3,220 g, 20 min at 4 °C
(Eppendorf 5810R)
1. INTRODUCTION
Pneumonia represents important infection in children under fiver years old. Even with
efficient vaccines, this disease in 2015 was globally responsible for 15% of all deaths in
children and Streptococcus pneumoniae is the most common infectious agent (WHO,
2015).
Bio-Manguinhos/Oswaldo Cruz Foundation supplies in Brazil the 10-valent
pneumococcal vaccine that contains 10 of the 92 pathogen´s serotypes. This vaccine is
obtained through fermentations and purification of the capsular polysaccharides of each
serotype, followed by chemical couplings to specific carrier proteins.
Based on protein expression in prokaryotic system and purification, this work presents a
proposal for a industrial process of only one recombinant protein antigen, the PsaA
(pneumococcal surface adhesin A, 37 kDa), potentially capable to act against most of all
prevalent serotypes of S. pneumoniae.
2. AIMS OF THE WORK
The aim of this work was to propose a process to obtain this recombinant antigen,
describing fermentation, purification and formulation steps which could be scalable to be
converted in an industrial process.
3. EXPERIMENTAL STEPS
Protein expression  Purification  Formulation
4. MATERIALS AND METHODS
4.1 Protein expression:
4.2 Purification:
5. RESULTS AND DISCUSSION
Protein expression
PreCasting NuvexNuPAGE 4-12% denaturanting gel of samples from DEAE Sepharose purification. Lane 1: molecular
weigh standard. Lanes 2, 3,4: extract from 16, 6 and 10 hours cultivation respectively at 15% elution gradient. Lanes 5,








[protein] initial  [protein] supernatant ∗ 	
[protein] initial
6. CONCLUSIONS
These data demonstrate that it´s possible to develop a recombinant antigen production
process considering to reduce the expression time in 60% from original process,
proposed in LARENTIS et al (2011). Furthermore E. coli fermentation presents several
advantages compared to native form production in S. pneumoniae. Purification steps
could be performed with techniques with large-scale application achieving yield around
30% with high purity levels. Formulation is a proposal for new approach for bacterial
vaccines administration that could be more acceptable for children and elderly, the most
affected group of this infection.
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Lane 2 – 16h 
expression
68.1%
Lane 3 – 6 h 
expression
73.7%













16 120.9 45.23 37.4 68.1
10 124.3 44.79 36.04 77.6
6 98.7 20.21 29.6 73.7
Stepwise gradient elution of PsaA 10-h expression in DEAE 
Sepharose FF. Vol inj. 5 mL, flow rate 5 mL/min (VC 25mL)
PsaA recovery in different time expression conditions when eluted at 15% of NaCl in gradient
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TB(24 g/L yeast extract, 12 g/L 
tryptone, 12.67 g/L K2HPO4, 2.31 g/L 
KH2PO4  0.4% glycerol )  
50mL
+













20 mM Tris/1 mM EDTA (pH 8) 
5 mL buffer/g of pellet
Ultrasonic cell disruptor 
Sonics & Material, Inc
18,514 g, 20 min at 4 °C 
Eppendorf 5810R centrifuge
XK 16/20 column filled 
with 25 mL of DEAE 
Sepharose
fast flow
Akta Pure system (GE Healthcare). 
PsaA fraction
15% step
Stepwise gradient: 4%, 15% and 100%
Buffer A : 20 mM Tris/1 mM EDTA (pH 8) 
Buffer B : 20 mM Tris/1 mM EDTA (pH 8) 1M NaCl.
Sephadex G-25 (medium) XK 
26/40 column (GE Healthcare)
Buffer PBS pH 8









Tangential Cross Flow 
Filtration






4.3 Dessalting using tangential
cross flow filtration (TFF):
Chitosan
0.25, 0.5, 0.75 and 1.0% mass
(Sigma, 80% deacetylation degree) 
+ 
1% (v/v) acetic acid 
+
1% (w/v) Tween 80 
pH 5.0
1 mL PsaA solution 
+




Stirring 200 rpm 60 min
Centrifugation 8609 g
Dessalting technique G-25 TFF
mL initial 15 279.6
mg/mL initial 5.25 1.98
mg initial 78.75 553.61
mL final 35 205.91
mg/mL final 2.08 2.19
mg final 72.8 450.94
Recovery (%) 92.4 81.4
Overall recovery for each 100 mg total protein




Dessalting G25 31.7 ----
Desalting TFF* ----- 27.9
* Initial result – technique not optimized
1  2  3   4          5  6   7   8   
SDS page  (12.5%) 
analysis after 
desalting. Samples 
with  20,15,10 and 5 
µg total protein
Lanes 1 - 4 ;G25
Lanes 5  8 10 kDa
membrane
50kDa
40 kDa
30 kDa
